Rivaroxaban, also known as BAY 59-7939, is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. If approved by the United States FDA, it will be marketed by Ortho-McNeil Pharmaceutical. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
相关文献及参考
Ansell, J., et al.: Drugs, 64, 1 (2004),
Eriksson, B., et al.: J. Thromb. Haemost., 3, 103 (2005),
Kubitza, D., et al.: Clin. Pharmacol. Ther., 78, 412 (2005),
安全信息
Warnings
IRRITANT
Storage condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).